The quest for safer and more efficacious targeted therapies drives the evolution of conjugates. PEGS Europe’s inaugural Engineering Conjugates conference will delve into the forefront of this rapidly advancing field. We invite speakers to showcase their strategies aimed at maximizing efficacy while minimizing off-target toxicities. We will explore the exciting field of novel formats and strategies for conditional payload release, new mechanisms of action, and innovative targeting approaches to expand the range of addressable targets. The conference will also highlight diverse payloads ranging from potent cytotoxins to immune-modulators, protein degraders and oligonucleotides, showcasing the power of conjugates in revolutionizing cancer treatment.

For more details on the conference, please contact:

Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5439
Email: mlangley@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com

Conference Programs

• Display of Biologics
• Engineering Antibodies
• Machine Learning: Part 2

• Antibody-Based Therapies
• Emerging Targets & Approaches
• Membrane Protein Targets

• Safety & Efficacy
• Advancing Multispecifics
• Engineering Bispecifics

• Modulating the TME
• Innovative CAR T Therapy
• Next-Gen Immunotherapies

• Optimisation & Developability
• Analytical Characterisation
• Protein Stability & Formulation

• Data Science & Engineering
• Optimising Expression
• Process Development

• Intro to Machine Learning
• Machine Learning: Part 1
• Machine Learning: Part 2

• Antibody-Based Therapies
• Engineering Conjugates
• Next-Gen Immunotherapies

---